2 February 2021
AARDEX Group and Pill Connect Ltd Partner to Empower Patient Adherence
Liege, Februray, 02, 2021 – Belgium-based AARDEX Group, the world leader in medication adherence solutions, today announced a strategic partnership with Pill Connect Ltd, an English company specializing in the design, development and manufacture of innovative medical...
1 February 2021
Blueberry Therapeutics announces extension of its Series B round with investment from Medical Incubator Japan and US Dermatology Syndicate
Blueberry Therapeutics Limited would like to announce that it has completed a £3.6m extension to the previously successful Series B Fundraising of £10.8m. This investment is from a Japanese investor, Medical Incubator Japan (MIJ) and a private syndicate of US Board...
28 January 2021
Chris Hall elected chairman of Pill Connect
MANCHESTER, U.K. — Pill Connect, formerly known as Elucid mHealth, has elected Chris Hall chairman of the company. Pill Connect is a world leader in medicine adherence monitoring and data capture on patient compliance. This follows the recent successful funding raise...
27 January 2021
Panthera continues to sign up new clinical trials across its UK network of dedicated clinical trial sites
Panthera continues to sign up new contracts despite COVID -19. Unlike many other clinical trial sites, Panthera’s dedicated sites do not mix clinical trial patients with other patients minimizing the risk of COVID -19 infection for both patients and staff. Many research...
21 January 2021
Manchester Imaging teams up with Michelson Diagnostics
Michelson Diagnostics Ltd, manufacturer of the world-leading VivoSight™ OCT skin imaging and measurement system, has teamed up with AI specialists Manchester Imaging Ltd, to aid dermatologists in the fight against skin cancer and other skin diseases. Michelson’s...
20 January 2021
Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform
OXFORD, United Kingdom and SAN JOSE, Calif. and SHANGHAI, China, Jan. 19, 2021 (GLOBE NEWSWIRE) -- WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platforms, and Oxford BioTherapeutics Ltd. (“OBT”), a...
14 January 2021
Maxwellia Announces Appointment of Jack Grimshaw as Finance Director
Maxwellia, the UK’s only dedicated expert medicines switching company, has appointed Jack Grimshaw as Finance Director, with broader accountability for Supply Chain & Logistics, Procurement, IT, Legal & HR. The appointment is a reflection of the company’s...
12 January 2021
Funding package announced for blister prevention firm Pellitec
The North West entrepreneurs behind PelliTec®, the innovative blister prevention pad, are celebrating as the National Institute of Health Research has awarded the company a grant to progress a ‘proof of concept’ study at Sheffield Teaching Hospitals NHS...
7 January 2021
Kite and Oxford Biotherapeutics Establish Cell therapy Research Collaboration in Blood Cancers and Solid Tumours
Santa Monica, Calif.; Oxford, UK; and San Jose, Calif., January 6, 2021 - Kite, a Gilead Company (Nasdaq: GILD), and Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based therapies...
5 January 2021
Panthera assists in AstraZeneca’s phase III trial of antibody combination for prevention of Covid-19
Panthera’s clinical trial sites in Preston, North Manchester and North London began dosing volunteers in the Phase III PROVENT trial which will evaluate AstraZeneca’s long-acting antibody combination, AZD7442, for the potential prevention of COVID-19. The...